Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Exclusion Criteria

• •Patients with contraindication to receive bevacizumab:
• •* Hypersensitivity to the active ingredient or to some of the formula excipients.
• •* Hypersensitivity to products derived from CHO cells or to other human recombinant antibodies or humanized antibodies.
• •Patients having received intravitreal antiangiogenic therapy prior to wet AMD treatment.
• •Patients receiving previous systemic antiangiogenic therapy.
• •Wet AMD in the healing period or disciform scar.
• •Pregnant, breastfeeding or childbearing-aged women.
• •Any person with choroidal neovascularization not associated to wet AMD.
• •History of retinal or intraocular surgery in the affected eye in the last three months.
• •Vitrectomy in the affected eye.
• •Any significant ocular infection, active or suspected, having compromised or able to compromise the eye to be studied.
• •Ocular inflammatory disease.
• •Myopia exceeding -8 diopters.
• •Extensive subfoveal subretinal hemorrhage \> 2 papillary diameter (PD).
• •Coexistence of other severe ocular diseases: uncontrolled ocular hypertension, terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy.
• •History of stroke or myocardial infarction in the last 6 months.
• •Patients with coagulopathies.
• •Patients physically or mentally disabled to participate in such visual tests.